首页 > 最新文献

Dermatology最新文献

英文 中文
A Bibliometrics of the Treatment of Alopecia Areata in the Past Twenty Years. 过去二十年治疗脱发的文献计量学。
IF 3.4 3区 医学 Q2 DERMATOLOGY Pub Date : 2024-01-01 Epub Date: 2023-11-08 DOI: 10.1159/000535043
Wen-Rong Luo, Gan Shen, Li-Hua Yang, Xiao-Hai Zhu

Background: Alopecia areata (AA) is an autoimmune disorder characterized by hair loss on the scalp, face, and other body areas. Despite affecting approximately 2% of the global population, there has been no previous bibliometric analysis specifically focusing on AA treatment that can guide researchers in exploring promising treatment options and directing future research efforts.

Summary: This study conducted a bibliometric analysis of AA treatment research, encompassing publications from 2003 to 2022. A total of 1,323 papers from 65 countries, predominantly led by the USA and China, were included in the analysis. The number of publications related to AA treatment showed a notable increase over the years. Prominent research institutions included the University of Manchester, Icahn School of Medicine at Mount Sinai, University of Miami, and Columbia University. Among the journals, Dermatologic Therapy stood out as the most popular, while the Journal of the American Academy of Dermatology appeared as the most frequently co-cited publication.

背景:斑秃(AA)是一种自身免疫性疾病,其特征是头皮、面部和其他身体部位的脱发。尽管影响了全球约2%的人口,但此前还没有专门针对AA治疗的文献计量分析,可以指导研究人员探索有前景的治疗方案并指导未来的研究工作。摘要:本研究对AA治疗研究进行了文献计量学分析,涵盖了2003年至2022年的出版物。该分析共收录了来自65个国家的1323篇论文,主要以美国和中国为首。多年来,与AA治疗相关的出版物数量显著增加。著名的研究机构包括曼彻斯特大学、西奈山伊坎医学院、迈阿密大学和哥伦比亚大学。在这些期刊中,《皮肤病学治疗》是最受欢迎的,而《美国皮肤病学会杂志》则是最常被引用的出版物。关键信息:1。这项文献计量学研究全面概述了AA治疗的研究趋势和进展。2.该分析确定了关键的研究热点,包括变体、富血小板血浆(PRP)、janus激酶(JAK)抑制剂和调节性T细胞(Treg)。3.专门研究AA的研究人员可以将这些发现作为有价值的参考,以加强他们的研究,并探索治疗AA的新途径。
{"title":"A Bibliometrics of the Treatment of Alopecia Areata in the Past Twenty Years.","authors":"Wen-Rong Luo, Gan Shen, Li-Hua Yang, Xiao-Hai Zhu","doi":"10.1159/000535043","DOIUrl":"10.1159/000535043","url":null,"abstract":"<p><strong>Background: </strong>Alopecia areata (AA) is an autoimmune disorder characterized by hair loss on the scalp, face, and other body areas. Despite affecting approximately 2% of the global population, there has been no previous bibliometric analysis specifically focusing on AA treatment that can guide researchers in exploring promising treatment options and directing future research efforts.</p><p><strong>Summary: </strong>This study conducted a bibliometric analysis of AA treatment research, encompassing publications from 2003 to 2022. A total of 1,323 papers from 65 countries, predominantly led by the USA and China, were included in the analysis. The number of publications related to AA treatment showed a notable increase over the years. Prominent research institutions included the University of Manchester, Icahn School of Medicine at Mount Sinai, University of Miami, and Columbia University. Among the journals, Dermatologic Therapy stood out as the most popular, while the Journal of the American Academy of Dermatology appeared as the most frequently co-cited publication.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"42-58"},"PeriodicalIF":3.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71520793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Smartphone Photographs of Chronic Urticaria Taken by Patients Are of Good Quality and Useful in the Clinic. 患者拍摄的慢性荨麻疹的智能手机照片质量良好,在临床上很有用。
IF 3.4 3区 医学 Q2 DERMATOLOGY Pub Date : 2024-01-01 Epub Date: 2023-11-04 DOI: 10.1159/000535027
Zarqa Ali, Jennifer Astrup Sørensen, Ditte Georgina Zhang, Misbah Noshela Ghazanfar, Johan Anker Chrom Allerup, Marcus Maurer, Emek Kocatürk, Christian Vestergaard, Simon Francis Thomsen

Background: Chronic urticaria (CU) is characterized by transient wheals and angioedema, which are often not present when patients see their treating physician.

Objective: The objective of this study was to evaluate the diagnostic value of smartphone photographs captured by patients prior to their first visit at an urticaria outpatient clinic.

Methods: A survey regarding the quality and utility of smartphone photographs of urticarial skin lesions in patients with CU attending the outpatient clinic for the first time was conducted. Up to three random patient-selected photographs of skin lesions were evaluated by a physician.

Results: Of 148 patients, 118 (79.7%) had taken photographs of their skin lesions prior to the consultation, and 75% took photographs with the intention of presenting it to their physician. The photographs were of wheals in 90% of the cases and angioedema in 8%. In total, 72% of the smartphone photographs had the skin lesion in focus, 64% had good resolution, and 48% had good lighting. Only 9% of the smartphone photographs were blurred, 10% had bad lighting, 4% had bad resolution, and 8% did not have the lesion in focus. Moreover, 86% of the smartphone photographs were found to be useful for clinical evaluation. At least one photograph of good/very good quality was presented by 86% of the patients, and 97% had at least one photograph that was useful for clinical evaluation.

Conclusion: Patients with CU often take smartphone photographs of their skin lesions on their own initiative prior to their first consultation to present the photographs to their physician. These smartphone photographs are very often of good quality and suitable for clinical evaluation.

背景:慢性荨麻疹(CU)以短暂性风团和血管性水肿为特征,患者在就诊时通常不会出现这些症状。目的:评估患者首次到荨麻疹门诊就诊前拍摄的智能手机照片的诊断价值。方法:对首次到门诊就诊的CU患者的荨麻疹皮肤病变的智能手机照片的质量和实用性进行调查。医生对多达三张随机选择的患者皮肤损伤照片进行了评估。结果:在148名患者中,118人(79.7%)在咨询前拍摄了他们的皮肤损伤照片,75%的患者拍摄照片是为了向医生展示。照片显示90%的病例为风团,8%为血管性水肿。总的来说,72%的智能手机照片聚焦了皮肤损伤,64%的照片分辨率良好,48%的照片照明良好。只有9%的智能手机照片模糊,10%的照片光线不好,4%的照片分辨率不好,8%的照片没有聚焦。此外,86%的智能手机照片被发现对临床评估有用。86%的患者至少提供了一张质量良好/非常好的照片,97%的患者至少有一张照片可用于临床评估。结论:CU患者通常会在第一次就诊前主动在智能手机上拍摄皮肤病变的照片,并将照片提交给医生。这些智能手机照片通常质量良好,适合临床评估。
{"title":"Smartphone Photographs of Chronic Urticaria Taken by Patients Are of Good Quality and Useful in the Clinic.","authors":"Zarqa Ali, Jennifer Astrup Sørensen, Ditte Georgina Zhang, Misbah Noshela Ghazanfar, Johan Anker Chrom Allerup, Marcus Maurer, Emek Kocatürk, Christian Vestergaard, Simon Francis Thomsen","doi":"10.1159/000535027","DOIUrl":"10.1159/000535027","url":null,"abstract":"<p><strong>Background: </strong>Chronic urticaria (CU) is characterized by transient wheals and angioedema, which are often not present when patients see their treating physician.</p><p><strong>Objective: </strong>The objective of this study was to evaluate the diagnostic value of smartphone photographs captured by patients prior to their first visit at an urticaria outpatient clinic.</p><p><strong>Methods: </strong>A survey regarding the quality and utility of smartphone photographs of urticarial skin lesions in patients with CU attending the outpatient clinic for the first time was conducted. Up to three random patient-selected photographs of skin lesions were evaluated by a physician.</p><p><strong>Results: </strong>Of 148 patients, 118 (79.7%) had taken photographs of their skin lesions prior to the consultation, and 75% took photographs with the intention of presenting it to their physician. The photographs were of wheals in 90% of the cases and angioedema in 8%. In total, 72% of the smartphone photographs had the skin lesion in focus, 64% had good resolution, and 48% had good lighting. Only 9% of the smartphone photographs were blurred, 10% had bad lighting, 4% had bad resolution, and 8% did not have the lesion in focus. Moreover, 86% of the smartphone photographs were found to be useful for clinical evaluation. At least one photograph of good/very good quality was presented by 86% of the patients, and 97% had at least one photograph that was useful for clinical evaluation.</p><p><strong>Conclusion: </strong>Patients with CU often take smartphone photographs of their skin lesions on their own initiative prior to their first consultation to present the photographs to their physician. These smartphone photographs are very often of good quality and suitable for clinical evaluation.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"357-361"},"PeriodicalIF":3.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71479305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Systematic Review and Bayesian Network Meta-Analysis of Medical Therapies for Lichen Planopilaris. 扁平苔藓药物治疗的系统综述和贝叶斯网络荟萃分析。
IF 3 3区 医学 Q2 DERMATOLOGY Pub Date : 2024-01-01 Epub Date: 2023-10-18 DOI: 10.1159/000534364
Husein Husein-ElAhmed, Sara Husein-ElAhmed

Background: Lichen planopilaris (LPP) is a primary chronic lymphocytic cutaneous disorder that selectively destroys the hair follicles, resulting in scarring alopecia. Unfortunately, current available treatments are not fully effective to stop hair loss, and the level of evidence for medical interventions is weak.

Objectives: The present article aimed to determine the efficacy of the different medical interventions in LPP through a network meta-analysis (NMA).

Methods: A systematic review and meta-analysis were performed including randomized trials that report the outcomes of lichen planopilaris activity index (LPPAI). These articles were pooled and a NMA was conducted.

Results: A total of seven studies were identified and included in meta-analysis, comprising 251 LPP patients. The NMA showed the mean difference in LLPAI was significantly superior with the combination of clobetasol plus N-acetylcysteine (mean difference: -2.0, 95% CI = -3.43 to -0.51) and the combination of clobetasol plus pentoxifylline (mean difference: -1.62, 95% CI = -3.0 to -0.25) compared to the treatment of reference (clobetasol). The NMA showed cyclosporine (mean difference: 2.05 95% CI = 0.68-3.49), methotrexate (mean difference: 1.95 95% CI = 1.23-3.17), the combination of methotrexate plus prednisolone (mean difference: 1.56 95% CI = 0.25-2.96) were significantly worse than hydroxychloroquine according to the differences in LLPAI.

Conclusion: This work is the first NMA in LPP and hence, it can be helpful in serving as an initial step toward better evidence-based decisions in the treatment of this challenging condition. We propose a triple-combined approach consisting of topical clobetasol, hydroxychloroquine, and N-acetylcysteine as resulted in the most effective approach. Considering the poor outcomes observed with pioglitazone, mycophenolate mofetil, and cyclosporine, it is advisable to contemplate the use of these medications in patients who have not responded adequately to more efficacious alternatives.

背景:扁平皮癣(LPP)是一种原发性慢性淋巴细胞性皮肤病,选择性破坏毛囊,导致瘢痕性脱发。不幸的是,目前可用的治疗方法并不能完全有效地阻止脱发,而且医学干预的证据水平也很弱。方法:进行系统综述和荟萃分析,包括报告扁平皮苔藓活性指数(LPPAI)结果的随机试验。将这些文章汇集在一起,并进行网络荟萃分析(NAM)。结果:共有7项研究被确定并纳入荟萃分析,包括251名LPP患者。NMA显示,与对照组(氯倍他索)相比,氯倍他索加N-乙酰半胱氨酸组合(平均差异:-2.0,95%CI=-3.43--0.51)和氯倍他索尔加戊氧芬组合(平均差:-1.62,95%CI=-3.0-0.25)的LLPAI的平均差异显着更高。NMA显示,根据LLPAI的差异,环孢菌素(平均差异:2.05 95%CI=0.68-3.49)、甲氨蝶呤(平均差异,1.95 95%CI=1.23-3.17)、甲氨蝶呤联合泼尼松(平均差异为1.56 95%CI=0.25-2.96)明显劣于羟氯喹。结论:这项工作是LPP中的第一个NMA,因此,它可以作为治疗这种具有挑战性的疾病的更好的循证决策的第一步。我们提出了一种由局部氯倍他索、羟氯喹和N-乙酰半胱氨酸组成的三重联合方法,这是最有效的方法。考虑到吡格列酮、霉酚酸酯和环孢菌素的不良疗效,建议考虑在对更有效的替代品反应不足的患者中使用这些药物。
{"title":"A Systematic Review and Bayesian Network Meta-Analysis of Medical Therapies for Lichen Planopilaris.","authors":"Husein Husein-ElAhmed, Sara Husein-ElAhmed","doi":"10.1159/000534364","DOIUrl":"10.1159/000534364","url":null,"abstract":"<p><strong>Background: </strong>Lichen planopilaris (LPP) is a primary chronic lymphocytic cutaneous disorder that selectively destroys the hair follicles, resulting in scarring alopecia. Unfortunately, current available treatments are not fully effective to stop hair loss, and the level of evidence for medical interventions is weak.</p><p><strong>Objectives: </strong>The present article aimed to determine the efficacy of the different medical interventions in LPP through a network meta-analysis (NMA).</p><p><strong>Methods: </strong>A systematic review and meta-analysis were performed including randomized trials that report the outcomes of lichen planopilaris activity index (LPPAI). These articles were pooled and a NMA was conducted.</p><p><strong>Results: </strong>A total of seven studies were identified and included in meta-analysis, comprising 251 LPP patients. The NMA showed the mean difference in LLPAI was significantly superior with the combination of clobetasol plus N-acetylcysteine (mean difference: -2.0, 95% CI = -3.43 to -0.51) and the combination of clobetasol plus pentoxifylline (mean difference: -1.62, 95% CI = -3.0 to -0.25) compared to the treatment of reference (clobetasol). The NMA showed cyclosporine (mean difference: 2.05 95% CI = 0.68-3.49), methotrexate (mean difference: 1.95 95% CI = 1.23-3.17), the combination of methotrexate plus prednisolone (mean difference: 1.56 95% CI = 0.25-2.96) were significantly worse than hydroxychloroquine according to the differences in LLPAI.</p><p><strong>Conclusion: </strong>This work is the first NMA in LPP and hence, it can be helpful in serving as an initial step toward better evidence-based decisions in the treatment of this challenging condition. We propose a triple-combined approach consisting of topical clobetasol, hydroxychloroquine, and N-acetylcysteine as resulted in the most effective approach. Considering the poor outcomes observed with pioglitazone, mycophenolate mofetil, and cyclosporine, it is advisable to contemplate the use of these medications in patients who have not responded adequately to more efficacious alternatives.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"103-110"},"PeriodicalIF":3.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49675476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Response to "Letter to the Editor on "Comparison of Social Media Content on Hidradenitis Suppurativa: A Cross-Sectional Study". 回应 "致编辑的信,关于 "社交媒体内容对扁平苔藓的影响比较:一项横断面研究"。
IF 3.4 3区 医学 Q2 DERMATOLOGY Pub Date : 2024-01-01 Epub Date: 2024-01-30 DOI: 10.1159/000536481
Anna Wolinska, Gregg Murray, Madonna Andrawis, Paula Beatty, Marta Costa Blasco, Claire Doyle, Orla Mc Feely, Lisa Murphy, Anne-Marie Tobin
{"title":"Response to \"Letter to the Editor on \"Comparison of Social Media Content on Hidradenitis Suppurativa: A Cross-Sectional Study\".","authors":"Anna Wolinska, Gregg Murray, Madonna Andrawis, Paula Beatty, Marta Costa Blasco, Claire Doyle, Orla Mc Feely, Lisa Murphy, Anne-Marie Tobin","doi":"10.1159/000536481","DOIUrl":"10.1159/000536481","url":null,"abstract":"","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"519-520"},"PeriodicalIF":3.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139641779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abrocitinib Provides Rapid and Sustained Improvement in Skin Pain and Is Associated with Improved Quality of Life Outcomes in Adult and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis. 阿罗西替尼能快速、持续地改善中重度特应性皮炎成人和青少年患者的皮肤疼痛,并能提高他们的生活质量。
IF 3.4 3区 医学 Q2 DERMATOLOGY Pub Date : 2024-01-01 Epub Date: 2023-12-11 DOI: 10.1159/000535285
Jacob P Thyssen, Anthony Bewley, Sonja Ständer, Carla Castro, Laurent Misery, Brian S Kim, Pinaki Biswas, Gary Chan, Daniela E Myers, Melissa Watkins, Justine Alderfer, Erman Güler, Jonathan I Silverberg

Background: Skin pain in atopic dermatitis (AD) increases with disease severity and is associated with substantial quality of life (QoL) burden.

Objectives: The aim of the study was to evaluate abrocitinib efficacy on skin pain and QoL in adults and adolescents with moderate-to-severe AD.

Methods: This post hoc analysis included data with abrocitinib administered as monotherapy (pooled phase 2b [NCT02780167] and phase 3 JADE MONO-1 [NCT03349060] and JADE MONO-2 [NCT03575871]) or in combination with topical therapy (phase 3 JADE COMPARE [NCT03720470] and JADE TEEN [NCT03796676]). Patients received oral, once-daily abrocitinib 200 mg, abrocitinib 100 mg, or placebo for 12 or 16 weeks (JADE COMPARE). Skin pain was rated using the Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) skin pain Numerical Rating Scale (NRS) item ("How painful was your skin over the past 24 h?") on a scale from 0 (not painful) to 10 (extremely painful). Itch (Peak Pruritus NRS) and QoL (Dermatology Life Quality Index or Children's Dermatology Life Quality Index) were assessed. Least squares mean (LSM) change from baseline was analyzed using mixed-effects repeated measures modeling.

Results: A total of 1,822 patients (monotherapy pool, n = 942; JADE COMPARE, n = 595; and JADE TEEN, n = 285) were analyzed. LSM change from baseline in PSAAD skin pain score was significantly greater with abrocitinib versus placebo from week 2 through week 12 or 16 across all 3 study populations and occurred in a dose-dependent manner. A greater proportion of patients achieved a ≥4-point improvement from baseline in PSAAD skin pain score with abrocitinib (200 mg and 100 mg) versus placebo in the monotherapy pool (56% and 38% vs. 12%; week 12), JADE COMPARE (72% and 52% vs. 26%; week 16), and JADE TEEN (51% and 60% vs. 31%; week 12). Additionally, a greater proportion of patients achieved a stringent threshold of skin pain improvement (PSAAD skin pain score <2) with abrocitinib versus placebo. Adults and adolescents who achieved a ≥4-point improvement in skin pain reported greater QoL improvement than those who did not achieve a ≥4-point improvement. A positive correlation (≥0.3) was observed between skin pain and QoL and separately between skin pain and itch across the 3 study populations.

Conclusion: Abrocitinib as monotherapy or in combination with topical therapy improved skin pain and was associated with improved QoL in both adults and adolescents with moderate-to-severe AD across all evaluated studies.

背景:特应性皮炎(AD)患者的皮肤疼痛会随着疾病严重程度的增加而加剧,并且与严重的生活质量(QoL)负担相关:评估阿昔替尼对中重度特应性皮炎成人和青少年患者皮肤疼痛和 QoL 的疗效:这项事后分析纳入了阿罗西替尼单药治疗(2b期[NCT02780167]和3期JADE MONO-1[NCT03349060]和MONO-2[NCT03575871]合并治疗)或与局部治疗(3期JADE COMPARE[NCT03720470]和JADE TEEN[NCT03796676]合并治疗)的数据。患者每天口服一次阿罗西替尼 200 毫克、阿罗西替尼 100 毫克或安慰剂,疗程为 12 或 16 周(JADE COMPARE)。皮肤疼痛采用特应性皮炎瘙痒和症状评估(PSAAD)皮肤疼痛数字评定量表(NRS)项目("过去24小时内您的皮肤有多疼痛?")进行评定,评分范围从0(不痛)到10(极度疼痛)。瘙痒(瘙痒峰值 NRS)和 QoL(皮肤科生活质量指数或儿童皮肤科生活质量指数)也得到了评估。使用混合效应重复测量模型分析了与基线相比的最小平方均值(LSM)变化:共分析了1822名患者(单药治疗组,942人;JADE COMPARE,595人;JADE TEEN,285人)。在所有3个研究人群中,从第2周到第12周或第16周,阿罗西替尼与安慰剂相比,PSAAD皮肤疼痛评分从基线开始的LSM变化显著增大,且呈剂量依赖性。在单药治疗组(56%和38% vs 12%;第12周)、JADE COMPARE(72%和52% vs 26%;第16周)和JADE TEEN(51%和60% vs 31%;第12周)中,阿罗西替尼(200毫克和100毫克)与安慰剂相比,PSAAD皮肤疼痛评分较基线改善≥4分的患者比例更高。此外,更多患者达到了严格的皮肤疼痛改善阈值(PSAAD 皮肤疼痛评分结论):在所有接受评估的研究中,阿罗西替尼单药治疗或联合外用疗法均可改善中重度AD成人和青少年患者的皮肤疼痛,并与QoL的改善相关。
{"title":"Abrocitinib Provides Rapid and Sustained Improvement in Skin Pain and Is Associated with Improved Quality of Life Outcomes in Adult and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis.","authors":"Jacob P Thyssen, Anthony Bewley, Sonja Ständer, Carla Castro, Laurent Misery, Brian S Kim, Pinaki Biswas, Gary Chan, Daniela E Myers, Melissa Watkins, Justine Alderfer, Erman Güler, Jonathan I Silverberg","doi":"10.1159/000535285","DOIUrl":"10.1159/000535285","url":null,"abstract":"<p><strong>Background: </strong>Skin pain in atopic dermatitis (AD) increases with disease severity and is associated with substantial quality of life (QoL) burden.</p><p><strong>Objectives: </strong>The aim of the study was to evaluate abrocitinib efficacy on skin pain and QoL in adults and adolescents with moderate-to-severe AD.</p><p><strong>Methods: </strong>This post hoc analysis included data with abrocitinib administered as monotherapy (pooled phase 2b [NCT02780167] and phase 3 JADE MONO-1 [NCT03349060] and JADE MONO-2 [NCT03575871]) or in combination with topical therapy (phase 3 JADE COMPARE [NCT03720470] and JADE TEEN [NCT03796676]). Patients received oral, once-daily abrocitinib 200 mg, abrocitinib 100 mg, or placebo for 12 or 16 weeks (JADE COMPARE). Skin pain was rated using the Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) skin pain Numerical Rating Scale (NRS) item (\"How painful was your skin over the past 24 h?\") on a scale from 0 (not painful) to 10 (extremely painful). Itch (Peak Pruritus NRS) and QoL (Dermatology Life Quality Index or Children's Dermatology Life Quality Index) were assessed. Least squares mean (LSM) change from baseline was analyzed using mixed-effects repeated measures modeling.</p><p><strong>Results: </strong>A total of 1,822 patients (monotherapy pool, n = 942; JADE COMPARE, n = 595; and JADE TEEN, n = 285) were analyzed. LSM change from baseline in PSAAD skin pain score was significantly greater with abrocitinib versus placebo from week 2 through week 12 or 16 across all 3 study populations and occurred in a dose-dependent manner. A greater proportion of patients achieved a ≥4-point improvement from baseline in PSAAD skin pain score with abrocitinib (200 mg and 100 mg) versus placebo in the monotherapy pool (56% and 38% vs. 12%; week 12), JADE COMPARE (72% and 52% vs. 26%; week 16), and JADE TEEN (51% and 60% vs. 31%; week 12). Additionally, a greater proportion of patients achieved a stringent threshold of skin pain improvement (PSAAD skin pain score &lt;2) with abrocitinib versus placebo. Adults and adolescents who achieved a ≥4-point improvement in skin pain reported greater QoL improvement than those who did not achieve a ≥4-point improvement. A positive correlation (≥0.3) was observed between skin pain and QoL and separately between skin pain and itch across the 3 study populations.</p><p><strong>Conclusion: </strong>Abrocitinib as monotherapy or in combination with topical therapy improved skin pain and was associated with improved QoL in both adults and adolescents with moderate-to-severe AD across all evaluated studies.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"243-253"},"PeriodicalIF":3.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10997245/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138800639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of the Impact of Night Shift Work on Disease Severity in Psoriatic Patients: A Case-Control Study with Clinical, Hormonal, and Immunological Evaluation. 评估夜班工作对银屑病患者病情严重程度的影响:一项通过临床、激素和免疫学评估进行的病例对照研究。
IF 3 3区 医学 Q2 DERMATOLOGY Pub Date : 2024-01-01 Epub Date: 2024-06-18 DOI: 10.1159/000539685
Giacomo Caldarola, Eleonora De Luca, Angelina Barini, Umberto Basile, Valeria Carnazzo, Andrea Chiricozzi, Barbara Tolusso, Elisa Gremese, Lucia Di Nardo, Ketty Peris, Clara De Simone

Introduction: Night shift work disrupts circadian rhythms and has been associated with immune system alterations and various health conditions. However, there is limited data regarding its impact on psoriasis. The aim of our study was to compare psoriasis severity and the hormonal and immunological profile in patients with a night shift work to those with a daytime occupation.

Methods: In this case-control study, we enrolled psoriatic patients aged >18 years engaged in night shift work and a control group of psoriatic patients with a daytime occupation. A further categorization was performed by the duration of night shift work: < or ≥7 days a month and < or ≥8 years. Disease severity was evaluated by PASI, BSA, and DLQI, and blood samples were taken to measure various hormonal and immunological markers. Univariable and multivariable analysis were performed to assess differences between the two groups.

Results: A total of 40 night shift workers were included, along with 36 patients in the control group. Patients who worked night shifts at least 7 days a month had significantly higher PASI scores (11.2 ± 6.6 vs. 8.5 ± 6.6; p = 0.04) and higher IL-8 serum (115.33 ± 463.65 pg/mL vs. 19.98 ± 29.78 pg/mL; p = 0.006) compared to patients who did not. Night shifts workers for at least 8 years had higher BMI (28.65 ± 4.56 vs. 25.32 ± 5.50, p = 0.010), and females had higher testosterone levels (0.46 ± 0.53 ng/mL vs. 0.23 ± 0.13 ng/mL; p = 0.055).

Conclusion: Night shift might increase psoriasis severity and have an impact on chronic inflammation, obesity, and hormonal imbalances.

引言夜班工作会扰乱昼夜节律,与免疫系统改变和各种健康问题有关。然而,有关夜班对银屑病影响的数据却很有限。我们的研究旨在比较夜班工作与日班工作患者的银屑病严重程度以及激素和免疫学特征:在这项病例对照研究中,我们招募了年龄为 18 岁、从事夜班工作的银屑病患者和日间工作的银屑病患者作为对照组。根据夜班工作时间的长短进行了进一步分类:<或每月≥7天和<或≥8年。通过PASI、BSA和DLQI评估疾病严重程度,并抽取血液样本测量各种激素和免疫标记物。为评估两组间的差异,进行了单变量和多变量分析:共纳入 40 名夜班工人和 36 名对照组患者。与不上夜班的患者相比,每月上夜班至少 7 天的患者的 PASI 评分明显更高(11.2 ± 6.6 vs 8.5 ± 6.6;P 0.04),血清中 IL-8 的含量也更高(115.33 ± 463.65 pg/ml vs 19.98 ± 29.78 pg/ml;P = 0.006)。至少工作 8 年的夜班工人的体重指数较高(28.65±4.56 对 25.32±5.50,P=0.010),女性的睾酮水平较高(0.46±0.53 ng/mL 对 0.23±0.13 ng/mL;P=0.055):结论:夜班可能会增加银屑病的严重程度,并对慢性炎症、肥胖和内分泌失调产生影响。
{"title":"Evaluation of the Impact of Night Shift Work on Disease Severity in Psoriatic Patients: A Case-Control Study with Clinical, Hormonal, and Immunological Evaluation.","authors":"Giacomo Caldarola, Eleonora De Luca, Angelina Barini, Umberto Basile, Valeria Carnazzo, Andrea Chiricozzi, Barbara Tolusso, Elisa Gremese, Lucia Di Nardo, Ketty Peris, Clara De Simone","doi":"10.1159/000539685","DOIUrl":"10.1159/000539685","url":null,"abstract":"<p><strong>Introduction: </strong>Night shift work disrupts circadian rhythms and has been associated with immune system alterations and various health conditions. However, there is limited data regarding its impact on psoriasis. The aim of our study was to compare psoriasis severity and the hormonal and immunological profile in patients with a night shift work to those with a daytime occupation.</p><p><strong>Methods: </strong>In this case-control study, we enrolled psoriatic patients aged &gt;18 years engaged in night shift work and a control group of psoriatic patients with a daytime occupation. A further categorization was performed by the duration of night shift work: &lt; or ≥7 days a month and &lt; or ≥8 years. Disease severity was evaluated by PASI, BSA, and DLQI, and blood samples were taken to measure various hormonal and immunological markers. Univariable and multivariable analysis were performed to assess differences between the two groups.</p><p><strong>Results: </strong>A total of 40 night shift workers were included, along with 36 patients in the control group. Patients who worked night shifts at least 7 days a month had significantly higher PASI scores (11.2 ± 6.6 vs. 8.5 ± 6.6; p = 0.04) and higher IL-8 serum (115.33 ± 463.65 pg/mL vs. 19.98 ± 29.78 pg/mL; p = 0.006) compared to patients who did not. Night shifts workers for at least 8 years had higher BMI (28.65 ± 4.56 vs. 25.32 ± 5.50, p = 0.010), and females had higher testosterone levels (0.46 ± 0.53 ng/mL vs. 0.23 ± 0.13 ng/mL; p = 0.055).</p><p><strong>Conclusion: </strong>Night shift might increase psoriasis severity and have an impact on chronic inflammation, obesity, and hormonal imbalances.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"665-670"},"PeriodicalIF":3.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141418299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identification of Novel Genetic Risk Variants Associated with Hidradenitis Suppurativa in an Exome Sequencing Cohort of 92,455 Individuals. 在 92,455 人的外显子组测序队列中发现与化脓性扁桃体炎相关的新型遗传风险变异。
IF 3 3区 医学 Q2 DERMATOLOGY Pub Date : 2024-01-01 Epub Date: 2024-10-11 DOI: 10.1159/000540359
Raghu P Metpally, Sangeetha Vishweswaraiah, Sarathbabu Krishnamurthy, Nazia Saiyed, Richard C Stahl, Alicia Golden, Andrew Denisenko, Jeffrey Staples, Claudia Gonzaga-Jauregui, David J Carey, Falk Bechara, Gregor B E Jemec, Heinric Williams, Uppala Radhakrishna

Introduction: Hidradenitis suppurativa (HS) is a prevalent and persistent inflammatory skin disorder, lacking a known cure or effective biomarkers for early diagnosis at present. The genetic determinants of HS have not been fully documented, but it is believed to result from a combination of genetic and environmental factors.

Methods: To identify relevant HS gene variants in sporadic HS patients, this study utilized longitudinal electronic health records (EHRs) and whole-exome sequencing. DNA exome sequencing data from 92,455 participant samples in the MyCode biobank, linked to Geisinger's EHR, were analyzed. This cohort included 1,092 HS cases and 91,363 healthy controls. The MyCode EHR has a median longitudinal follow-up of 15 years per participant, with an average of 87 clinical encounters, 687 laboratory tests, and 7 procedures.

Results: There were 1,092 (901 females and 191 males) participants aged 14-89 years (median 47 years) with HS (L73.2), indicating a 1.18% prevalence and accounting for a 4.7:1 female-to-male ratio among the individuals presenting for clinical care. γ-secretase complex, syndromic, and autoinflammatory gene variants were assessed. Potential pathogenic variants were identified among 66 individuals in the HS genes studied. Molecularly, the estimated HS variant prevalence was 1:1,400 in the cohort, 12.3% of variant carriers had HS diagnosis in EHR.

Conclusions: Using longitudinal EHR data, genomic screening identified HS-associated gene variants in a defined group of sporadic HS patients to augment the clinical diagnosis, particularly in cases of ambiguity. Based on this study, the field of skin disorders can benefit from a personalized approach to HS diagnosis using large-scale sequencing.

简介化脓性扁平湿疹(HS)是一种常见的顽固性炎症性皮肤病,目前尚无治愈方法或有效的早期诊断生物标志物。HS的遗传决定因素尚未被完全记录,但据信它是由遗传和环境因素共同作用的结果:为了确定散发性 HS 患者的相关 HS 基因变异,本研究采用了纵向电子健康记录(EHR)和全外显子组测序技术。该研究分析了与 Geisinger 电子健康记录相连的 MyCode 生物库中 92,455 份参与者样本的 DNA 外显子组测序数据。该队列包括 1,092 例 HS 病例和 91,363 例健康对照。MyCode EHR对每位参与者的纵向随访中位数为15年,平均87次临床就诊、687次实验室检测和7次手术:共有 1,092 名(901 名女性和 191 名男性)14-89 岁(中位数 47 岁)的参与者患有 HS(L73.2),患病率为 1.18%,临床就诊者中的男女比例为 4.7:1。对γ-分泌酶复合体、综合征和自身炎症基因变异进行了评估。在所研究的 66 名患者中发现了 HS 基因的潜在致病变异。从分子角度看,估计队列中的 HS 变异发生率为 1:1,400,12.3% 的变异携带者在 EHR 中被诊断为 HS:结论:通过纵向电子病历数据,基因组筛查在一组明确的散发性HS患者中发现了HS相关基因变异,从而增强了临床诊断,尤其是在诊断不明确的情况下。基于这项研究,利用大规模测序对HS进行个性化诊断可使皮肤病领域受益匪浅。
{"title":"Identification of Novel Genetic Risk Variants Associated with Hidradenitis Suppurativa in an Exome Sequencing Cohort of 92,455 Individuals.","authors":"Raghu P Metpally, Sangeetha Vishweswaraiah, Sarathbabu Krishnamurthy, Nazia Saiyed, Richard C Stahl, Alicia Golden, Andrew Denisenko, Jeffrey Staples, Claudia Gonzaga-Jauregui, David J Carey, Falk Bechara, Gregor B E Jemec, Heinric Williams, Uppala Radhakrishna","doi":"10.1159/000540359","DOIUrl":"10.1159/000540359","url":null,"abstract":"<p><strong>Introduction: </strong>Hidradenitis suppurativa (HS) is a prevalent and persistent inflammatory skin disorder, lacking a known cure or effective biomarkers for early diagnosis at present. The genetic determinants of HS have not been fully documented, but it is believed to result from a combination of genetic and environmental factors.</p><p><strong>Methods: </strong>To identify relevant HS gene variants in sporadic HS patients, this study utilized longitudinal electronic health records (EHRs) and whole-exome sequencing. DNA exome sequencing data from 92,455 participant samples in the MyCode biobank, linked to Geisinger's EHR, were analyzed. This cohort included 1,092 HS cases and 91,363 healthy controls. The MyCode EHR has a median longitudinal follow-up of 15 years per participant, with an average of 87 clinical encounters, 687 laboratory tests, and 7 procedures.</p><p><strong>Results: </strong>There were 1,092 (901 females and 191 males) participants aged 14-89 years (median 47 years) with HS (L73.2), indicating a 1.18% prevalence and accounting for a 4.7:1 female-to-male ratio among the individuals presenting for clinical care. γ-secretase complex, syndromic, and autoinflammatory gene variants were assessed. Potential pathogenic variants were identified among 66 individuals in the HS genes studied. Molecularly, the estimated HS variant prevalence was 1:1,400 in the cohort, 12.3% of variant carriers had HS diagnosis in EHR.</p><p><strong>Conclusions: </strong>Using longitudinal EHR data, genomic screening identified HS-associated gene variants in a defined group of sporadic HS patients to augment the clinical diagnosis, particularly in cases of ambiguity. Based on this study, the field of skin disorders can benefit from a personalized approach to HS diagnosis using large-scale sequencing.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"739-749"},"PeriodicalIF":3.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142460189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Factors Associated with Severe Hidradenitis Suppurativa, Using Hurley Staging and Metascore. 使用赫利分期法和 Metascore 测量与重度化脓性角膜炎相关的因素。
IF 3 3区 医学 Q2 DERMATOLOGY Pub Date : 2024-01-01 Epub Date: 2024-10-11 DOI: 10.1159/000541052
Mathieu Daoud, Mariano Suppa, Farida Benhadou, Stéphanie Heudens, Anne-Sophie Sarkis, Hassane Njimi, Sara K Saunte, Lila Desmarest, Carmen Orte Cano, Céline Dandoy, Laura Nobile, Margot Fontaine, Mathilde Daxhelet, Jalila Karama, Jonathan M White, Gregor B E Jemec, Véronique Del Marmol

Introduction: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease for which certain risk factors are well known: obesity and smoking (in particular). However, the factors associated with more severe conditions, and therefore potential aggravators of the disease, remain a matter of debate. Our study aims to determine the clinical factors associated with severe HS using several severity scores.

Methods: The data were obtained via the ERHS questionnaire from patients exclusively recruited at Erasme Hospital in Brussels. The severity of HS was firstly estimated by the Hurley score, and secondly by a metascore, a system combining the iHS4, HS-PGA, SAHS, and DLQI. Univariable and multivariable analyses were performed.

Results: Six hundred and forty-seven patients were included in the Hurley analysis, and 456 patients in the metascore analysis. In multivariable analysis, men have a more severe metascore than women (odds ratio [OR] = 1.89, p = 0.022), smoking was associated with a more severe disease according to metascore, especially in mild cases (OR = 0.76, p = 0.043), and an elevated body mass index was associated with having Hurley stage III disease compared to Hurley I or II disease (OR = 1.09, p = 0.001). A significant association is also shown between blood pressure and Hurley stage (OR = 0.97, p = 0.025). Self-reports of nonsteroidal anti-inflammatory drugs aggravating the disease is also a factor associated with greater severity according to the metascore (OR = 0.12, p = 0.008). Finally, several locations of HS lesions were associated with greater severity, in particular the armpits according to the metascore (OR = 0.29, p < 0.001), and the perianal area according to the Hurley score (OR = 0.15, p < 0.001).

Conclusion: HS seems to be more severe in men; smoking seems to aggravate mild cases of HS, while increased body mass index plays a major role in the transition from Hurley II to Hurley III.

导言化脓性扁平湿疹(HS)是一种慢性炎症性皮肤病,其某些风险因素众所周知:肥胖和吸烟(尤其是)。然而,与更严重病情相关的因素,以及因此可能导致病情加重的因素,仍是一个争论不休的问题。我们的研究旨在通过几种严重程度评分来确定与严重 HS 相关的临床因素:方法:我们通过 ERHS 问卷获得了布鲁塞尔 Erasme 医院专门招募的患者的数据。HS的严重程度首先由Hurley评分估算,其次由metascore评分估算,该系统结合了iHS4、HS-PGA、SAHS和DLQI。进行了单变量和多变量分析:有 647 名患者被纳入赫利分析,456 名患者被纳入 metascore 分析。在多变量分析中,男性的 metascore 比女性更严重(比值比 [OR] = 1.89,p = 0.022),根据 metascore,吸烟与更严重的疾病相关,尤其是在轻度病例中(OR = 0.76,p = 0.043),与 Hurley I 或 II 期疾病相比,体重指数升高与 Hurley III 期疾病相关(OR = 1.09,p = 0.001)。血压与 Hurley 分期之间也存在明显关联(OR = 0.97,p = 0.025)。自我报告使用非甾体类抗炎药会加重病情,这也是根据 metascore(OR = 0.12,p = 0.008)判断病情严重程度的一个相关因素。最后,HS病变的几个部位与病情的严重程度有关,尤其是根据 metascore(OR = 0.29,p <0.001)得出的腋窝部位和根据 Hurley 评分得出的肛周部位(OR = 0.15,p <0.001):结论:HS似乎在男性中更为严重;吸烟似乎会加重轻度HS的病情,而体重指数的增加在从Hurley II到Hurley III的转变过程中起着重要作用。
{"title":"Factors Associated with Severe Hidradenitis Suppurativa, Using Hurley Staging and Metascore.","authors":"Mathieu Daoud, Mariano Suppa, Farida Benhadou, Stéphanie Heudens, Anne-Sophie Sarkis, Hassane Njimi, Sara K Saunte, Lila Desmarest, Carmen Orte Cano, Céline Dandoy, Laura Nobile, Margot Fontaine, Mathilde Daxhelet, Jalila Karama, Jonathan M White, Gregor B E Jemec, Véronique Del Marmol","doi":"10.1159/000541052","DOIUrl":"10.1159/000541052","url":null,"abstract":"<p><strong>Introduction: </strong>Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease for which certain risk factors are well known: obesity and smoking (in particular). However, the factors associated with more severe conditions, and therefore potential aggravators of the disease, remain a matter of debate. Our study aims to determine the clinical factors associated with severe HS using several severity scores.</p><p><strong>Methods: </strong>The data were obtained via the ERHS questionnaire from patients exclusively recruited at Erasme Hospital in Brussels. The severity of HS was firstly estimated by the Hurley score, and secondly by a metascore, a system combining the iHS4, HS-PGA, SAHS, and DLQI. Univariable and multivariable analyses were performed.</p><p><strong>Results: </strong>Six hundred and forty-seven patients were included in the Hurley analysis, and 456 patients in the metascore analysis. In multivariable analysis, men have a more severe metascore than women (odds ratio [OR] = 1.89, p = 0.022), smoking was associated with a more severe disease according to metascore, especially in mild cases (OR = 0.76, p = 0.043), and an elevated body mass index was associated with having Hurley stage III disease compared to Hurley I or II disease (OR = 1.09, p = 0.001). A significant association is also shown between blood pressure and Hurley stage (OR = 0.97, p = 0.025). Self-reports of nonsteroidal anti-inflammatory drugs aggravating the disease is also a factor associated with greater severity according to the metascore (OR = 0.12, p = 0.008). Finally, several locations of HS lesions were associated with greater severity, in particular the armpits according to the metascore (OR = 0.29, p < 0.001), and the perianal area according to the Hurley score (OR = 0.15, p < 0.001).</p><p><strong>Conclusion: </strong>HS seems to be more severe in men; smoking seems to aggravate mild cases of HS, while increased body mass index plays a major role in the transition from Hurley II to Hurley III.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"713-731"},"PeriodicalIF":3.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142460187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum. 勘误。
IF 3 3区 医学 Q2 DERMATOLOGY Pub Date : 2024-01-01 Epub Date: 2024-08-30 DOI: 10.1159/000540927
{"title":"Erratum.","authors":"","doi":"10.1159/000540927","DOIUrl":"10.1159/000540927","url":null,"abstract":"","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"928"},"PeriodicalIF":3.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142105300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patient-Reported Satisfaction with Hair Regrowth in a Study of Ritlecitinib in Alopecia Areata: Results from ALLEGRO-2b/3. 利特西替尼治疗脱发研究中患者对毛发再生满意度的报告:ALLEGRO-2b/3 的结果。
IF 3 3区 医学 Q2 DERMATOLOGY Pub Date : 2024-01-01 Epub Date: 2024-06-27 DOI: 10.1159/000539536
Rodney Sinclair, Ernest H Law, Xingqi Zhang, Fan Zhang, Lynne Napatalung, Samuel H Zwillich, Brett King, Natasha Mesinkovska

Introduction: Patients with alopecia areata (AA) report high levels of dissatisfaction with commonly used treatments. Patient-reported outcomes are essential to understanding patients' experiences with AA treatments. The objective of this study was to evaluate patient-reported satisfaction with hair growth among patients with AA receiving ritlecitinib or placebo and the correlation between clinician-assessed efficacy and patient-reported satisfaction.

Methods: In the ALLEGRO-2b/3 (NCT03732807) trial, patients with AA and ≥50% scalp hair loss were randomized to daily ritlecitinib or placebo for 24 weeks, with a 24-week extension of continued ritlecitinib or switch from placebo to ritlecitinib. The Patient Satisfaction with Hair Growth (P-Sat) measure evaluated patients' satisfaction with hair growth in 3 domains: amount, quality, and overall satisfaction with hair growth. The prespecified analysis evaluated the proportion of patients who were slightly, moderately, or very satisfied with hair growth. Several post hoc analyses assessed the proportion of patients who were moderately/very satisfied and moderately/very dissatisfied and calculated polyserial correlations between change from baseline (CFB) in Severity of Alopecia Tool (SALT) and P-Sat scores at weeks 24 and 48.

Results: At week 24, the proportion of patients (N = 718) reporting satisfaction (slightly, moderately, or very satisfied) overall with their hair growth ranged from 36.4% in the ritlecitinib 10-mg group (evaluated for dose ranging only) to 67.5% in the 200/50-mg group versus 22.6% in the placebo groups. In patients randomized to ritlecitinib, the proportion who were satisfied increased or was maintained at week 48. A substantially greater proportion of placebo patients who switched to ritlecitinib reported satisfaction at week 48 than at week 24. Similar results were observed for patient satisfaction with the amount and quality of hair growth. In the post hoc analyses defining satisfaction as moderately/very satisfied and dissatisfaction as moderately/very dissatisfied, the benefit of ritlecitinib was also observed. All P-Sat domain scores strongly correlated with CFB-SALT scores at weeks 24 (range 0.73-0.76; p < 0.05) and 48 (0.74-0.77; p < 0.05).

Conclusions: Patients receiving active ritlecitinib doses reported favorable results versus placebo in satisfaction with hair growth up to week 48. High concordance was observed between improvement in scalp hair growth evaluated by clinicians and patient-reported satisfaction.

导言:斑秃(AA)患者对常用治疗方法的不满意度很高。患者报告的结果对于了解患者对 AA 治疗的体验至关重要。本研究旨在评估接受利特西替尼或安慰剂治疗的 AA 患者报告的头发生长满意度,以及临床医生评估的疗效与患者报告的满意度之间的相关性:在ALLEGRO-2b/3 (NCT03732807)试验中,头皮脱发≥50%的AA患者被随机分配到每日服用瑞替西替尼或安慰剂,为期24周,延长24周后继续服用瑞替西替尼或从安慰剂换成瑞替西替尼。患者对毛发生长的满意度(P-Sat)测量从3个方面评估患者对毛发生长的满意度:毛发生长的数量、质量和总体满意度。预设分析评估了对头发生长略微满意、比较满意或非常满意的患者比例。几项事后分析评估了中度/非常满意和中度/非常不满意患者的比例,并计算了第24周和第48周脱发严重程度工具(SALT)和P-Sat评分与基线相比的变化(CFB)之间的多序列相关性:第24周时,对头发生长总体表示满意(略微满意、比较满意或非常满意)的患者比例(718人)从利特西替尼10毫克组的36.4%(仅评估剂量范围)到200/50毫克组的67.5%,而安慰剂组为22.6%。在随机接受利特西替尼治疗的患者中,满意的比例在第48周时有所增加或保持不变。改用利特西替尼治疗的安慰剂患者中,第48周满意的比例大大高于第24周。在患者对毛发生长数量和质量的满意度方面也观察到了类似的结果。在将满意度定义为 "中度/非常满意 "和将不满意度定义为 "中度/非常不满意 "的事后分析中,也观察到了利特西替尼的益处。在第24周(范围为0.73-0.76;P<0.05)和第48周(0.74-0.77;P<0.05),所有P-Sat域得分均与CFB-SALT得分密切相关:结论:与安慰剂相比,接受瑞替尼有效剂量治疗的患者在第48周之前对毛发生长的满意度表现良好。临床医生评估的头皮毛发生长改善情况与患者报告的满意度高度一致:试验注册:Clinicaltrials.gov NCT0373280。
{"title":"Patient-Reported Satisfaction with Hair Regrowth in a Study of Ritlecitinib in Alopecia Areata: Results from ALLEGRO-2b/3.","authors":"Rodney Sinclair, Ernest H Law, Xingqi Zhang, Fan Zhang, Lynne Napatalung, Samuel H Zwillich, Brett King, Natasha Mesinkovska","doi":"10.1159/000539536","DOIUrl":"10.1159/000539536","url":null,"abstract":"<p><strong>Introduction: </strong>Patients with alopecia areata (AA) report high levels of dissatisfaction with commonly used treatments. Patient-reported outcomes are essential to understanding patients' experiences with AA treatments. The objective of this study was to evaluate patient-reported satisfaction with hair growth among patients with AA receiving ritlecitinib or placebo and the correlation between clinician-assessed efficacy and patient-reported satisfaction.</p><p><strong>Methods: </strong>In the ALLEGRO-2b/3 (NCT03732807) trial, patients with AA and ≥50% scalp hair loss were randomized to daily ritlecitinib or placebo for 24 weeks, with a 24-week extension of continued ritlecitinib or switch from placebo to ritlecitinib. The Patient Satisfaction with Hair Growth (P-Sat) measure evaluated patients' satisfaction with hair growth in 3 domains: amount, quality, and overall satisfaction with hair growth. The prespecified analysis evaluated the proportion of patients who were slightly, moderately, or very satisfied with hair growth. Several post hoc analyses assessed the proportion of patients who were moderately/very satisfied and moderately/very dissatisfied and calculated polyserial correlations between change from baseline (CFB) in Severity of Alopecia Tool (SALT) and P-Sat scores at weeks 24 and 48.</p><p><strong>Results: </strong>At week 24, the proportion of patients (N = 718) reporting satisfaction (slightly, moderately, or very satisfied) overall with their hair growth ranged from 36.4% in the ritlecitinib 10-mg group (evaluated for dose ranging only) to 67.5% in the 200/50-mg group versus 22.6% in the placebo groups. In patients randomized to ritlecitinib, the proportion who were satisfied increased or was maintained at week 48. A substantially greater proportion of placebo patients who switched to ritlecitinib reported satisfaction at week 48 than at week 24. Similar results were observed for patient satisfaction with the amount and quality of hair growth. In the post hoc analyses defining satisfaction as moderately/very satisfied and dissatisfaction as moderately/very dissatisfied, the benefit of ritlecitinib was also observed. All P-Sat domain scores strongly correlated with CFB-SALT scores at weeks 24 (range 0.73-0.76; p < 0.05) and 48 (0.74-0.77; p < 0.05).</p><p><strong>Conclusions: </strong>Patients receiving active ritlecitinib doses reported favorable results versus placebo in satisfaction with hair growth up to week 48. High concordance was observed between improvement in scalp hair growth evaluated by clinicians and patient-reported satisfaction.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"767-777"},"PeriodicalIF":3.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11651339/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141455829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Dermatology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1